Sam Possemiers

Sam Possemiers

Company: MRM Health

Job title: CEO


MH002, the first Optimized Consortia Therapeutic in Clinical Development for Ulcerative Colitis, Manufactured as Single Drug Substance 11:20 am

MH002 is an optimized combination of 6 commensal bacteria, rationally designed to target multiple key disease-modifying mechanisms of action in IBD MH002 is in clinical development in a Phase 1b/2a study in mild-to-moderate UC patients, with a lead extension program ongoing First application of MRM Health’s Microbiome Optimization TechnologyTM, anticipated to outperform conventional consortia with…Read more

day: Track A - Afternoon - Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.